CytoSorbents Corporation to Present at the Rodman & Renshaw Global Investment Conference
MONMOUTH JUNCTION, NJ–(Marketwire – Sep 8, 2010) – CytoSorbents Corporation (OTCBB: CTSO), a vicious caring focused association regulating red red red red red blood catharsis to provide life-threatening illnesses, voiced that Dr. Phillip Chan, Chief Executive Officer, will benefaction at the 12th Annual Healthcare Conference at the Rodman & Renshaw Global Investment Conference. The discussion will take place at the New York Palace Hotel in New York City from Sep 12-15, 2010. Dr. Chan’s display will take place on Tuesday, Sep 14th at 5:45PM EDT in the Winslow Salon. Please check the discussion report for any scheduling updates. http://www.rodmanandrenshaw.com/conferences?id=51.
An audio webcast of the slip display will be accessible for 90 days after the eventuality at http://www.wsw.com/webcast/rrshq18/ctso. An electronic duplicate of the display will be done accessible on email request.
About CytoSorbents and CytoSorb™
CytoSorbents Corporation, and the handling auxiliary CytoSorbents, Inc., is a vicious caring focused healing device association in clinical trials to provide serious sepsis, mostly called “overwhelming infection,” with a novel red red red red red blood catharsis device called CytoSorb™. Severe sepsis afflicts some-more than 1 million people in the United States and an estimated eighteen million people worldwide any year, murdering one in each 3 patients notwithstanding the most appropriate treatment. In the United States, some-more die from serious sepsis than from possibly heart attacks, strokes or any singular form of cancer. Severe sepsis is typically triggered by bacterial infections similar to pneumonia, or viral infections similar to influenza. However, it is the body’s aberrant defence reply to the trigger that leads to serious inflammation and the unregulated, large prolongation of cytokines, mostly called “cytokine storm,” that afterwards causes multi-organ disaster and mostly death. CytoSorb™ is a cartridge containing rarely porous polymer beads that have been written to filter cytokines and provide potentially deadly cytokine storm. As red red red red red blood is pumped regularly by the CytoSorb™ cartridge regulating customary dialysis equipment, the beads connect and remove cytokines and alternative toxins from blood. The treated with colour red red red red red blood is afterwards returned to the patient. The Company is now conducting the European Sepsis Trial — a multi-center, randomized, tranquil clinical hearing regulating CytoSorb™ to provide up to 100 patients with serious sepsis in the environment of respiratory failure. Pending a successful trial, the Company will find CE Mark capitulation and commercialization of CytoSorb™ in the European Union. Importantly, cytokine rebate around CytoSorb™ has extended qualification to a series of alternative vicious caring diseases where cytokine charge plays a unpropitious role, together with bake and fume transformation injury, trauma, strident respiratory trouble syndrome, modernized influenza, strident pancreatitis and other. CytoSorb™ is one of a series of opposite resins written for assorted healing applications, together with softened dialysis, the intensity diagnosis of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during diagnosis of cancer with tall sip informal chemotherapy, drug detoxification and others. Additional report is accessible for download on the Company’s website: www.cytosorbents.com.
Forward-Looking Statements
This press recover includes forward-looking statements dictated to validate for the protected bay from guilt determined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press recover have been not promises or guarantees and have been theme to risks and uncertainties that could means the tangible formula to talk about materially from those anticipated. These statements have been formed on management’s stream expectations and assumptions and have been of course theme to doubt and changes in circumstances. We counsel you not to place unjustified faith on any such forward-looking statements. Actual formula might talk about materially from those voiced or pragmatic by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc hold that the first risk factors include, but have been not singular to: obtaining supervision approvals together with compulsory FDA and CE Mark approvals; capability to successfully rise blurb operations; coherence on key personnel; acceptance of the Company’s healing inclination in the marketplace; the result of tentative and intensity litigation; correspondence with bureaucratic regulations; faith on investigate and contrast comforts of assorted universities and institutions; the capability to acquire competent financing in the destiny when needed; product guilt risks; singular production experience; singular marketing, sales and placement experience; marketplace acceptance of the Company’s products; competition; astonishing changes in technologies and technological advances; and alternative factors minute in the Company’s Form 10-K filed with the SEC on Apr 9, 2010, that is accessible at http://www.sec.gov.
